A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

This Phase 3 study tests whether adding a PD-1 immune checkpoint inhibitor and an anti-blood vessel drug to standard chemotherapy after surgery works better than chemotherapy alone in women with triple-negative breast cancer (a type that lacks hormone receptors and HER2). **You may be eligible if...** - You are a woman between 18 and 70 years old - You have stage IIA–IIIC triple-negative breast cancer that has been surgically removed - Your cancer was node-positive (lymph nodes were involved) - Surgery was completed within the past 8 weeks - You are in good general health (ECOG 0 or 1) with adequate organ function **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have had any systemic cancer treatment prior to joining (this is for post-surgery adjuvant therapy) - You have serious heart, liver, kidney, or immune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.